ITL, Robert H. Lurie Comprehensive Cancer Center sign drug development collaboration

The collaboration targets the clinical activity and side-effect profile of the study drugs. The pancreatic cancer and breast cancer are the first target clinical indications under consideration.

Immunovative Therapies founder and president Dr. Michael Har-Noy said, "Northwestern has a world-class team of physicians and scientists dedicated to bringing patients the newest technologies and exploring the newest methods to provide effective and low-toxic therapies aimed to help improve the quality of life of cancer patients."

Pursuant to the collaboration, Immunovative will provide the study drugs to Northwestern and transfer technology for immunological monitoring of patient blood and tumor samples and for producing mouse versions of the study drugs.

Northwestern will conduct investigator-initiated clinical trials of study drugs and tests new ideas for improving the drugs or combining them with other drugs in both animal and human trials.

The Northwestern University Robert H. Lurie Comprehensive Cancer Center director Dr. Steven Rosen said, "The immunological concepts developed by Immunovative represent a novel approach to immunotherapy and the initial clinical data suggests that these new concepts may be the breakthrough we are looking for to advance immunotherapy to clinical practice."